TITLE PAGE

2 Title

1

5

11

19

- Epidemiological, Clinical Characteristics and Risk Factors for Severe Condition and 3
- ICU Admission of COVID-19 Patients of Early Stage in China: A review 4
- **Authors** 6
- Qinwei Fu 1*, Wenjuan Wu M.D²*, Yang Liu M.D¹*, Heyin Huang M.D³*, Peihai 7
- Zhang M.D¹*, Xinrong Li M.D¹*, Ying Liu M.D¹*, Lanzhi Zhang¹, Hui Yang¹, Xin 8
- Zhang⁴, Qinxiu Zhang M.D^{1,5#}, Chaolin Huang M.D^{2#} 9
- 10 *Contributed equally

Author's affiliation and address 12

- ¹ Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 13
- ² Jin Yin-tan Hospital, Wuhan, China. 14
- ³ Chengdu University of Traditional Chinese Medicine, Chengdu, China. 15
- ⁴ Southwest Medical University, Luzhou, China. 16
- ⁵ School of Medical and Life Sciences, Chengdu University of Traditional Chinese 17
- 18 Medicine, Chengdu, China.

#Correspondence to: 20

- 1. Prof. Oinxiu Zhang, School of Medical and Life Sciences, Chengdu University of 21
- Traditional Chinese Medicine, Chengdu, 610041, China; Hospital of Chengdu 22
- University of Traditional Chinese Medicine, Chengdu, 610072, China. E-mail: 23
- zhqinxiu@163.com. Phone: +86 18980880173. 24
- 25 NOTE: The reference representation of the property of the p

88071718@gg.com. Phone: +86 15307173189. 1

- **Funding**
- 4 None.

2

3

5

8

9

- Copyright form disclosure: The authors have disclosed that they do not have any 6
- 7 potential conflicts of interest.

ABSTRACT

- Objective: Some retrospective studies reporting epidemiological, 10
- characteristics of COVID-19 patients of early stage were published. We aim to provide 11
- 12 an overview of epidemiological and clinical characteristics of the COVID-19 patients,
- and identification, treatment of early stage, especially for the patients with poor 13
- 14 prognosis.
- Data Sources: PubMed, CNKI and Google Scholar. 15
- Study Selection: We searched for published retrospective studies that described 16
- epidemiological and clinical characteristics of confirmed COVID-19 patients in China 17
- by April 14th, 2020 with search terms. Some studies were excluded according to criteria. 18
- 19 Finally, 53 studies were included.
- Data Extraction: Characteristics of the COVID-19 patients available from included 20
- articles were extracted, reorganized and recorded into electronic data forms. 21
- Data Synthesis: Characteristics of patients in the included studies were summarized and 22
- analyzed for median-interquartile ranges and univariable odds ratio. 23
- Conclusion: This study summarized, analyzed and compared epidemiological, clinical 24
- 25 characteristics and estimated univariable risk factors among confirmed COVID-19

patients either in former epicenter, in severe condition, with ICU admission or not of early stage. Higher proportions of patients were found to have older age and more comorbidities, typical characteristics on admission and complications either in former epicenter, with severe condition or ICU admission. No evidence showed that patients who were male or had smoking history had higher susceptibility, but they were significant risk factors for severe condition. Some self-implementable traditional Chinese medicine therapies conducted for immunity improvement, control of comorbidities and reduction of some medicine intake. Limited evidence revealed that some characteristics of the disease might be changing with human-to-human transmission, and more research, especially international collaboration, is needed.

KRY WORDS

13 COVID-19; Characteristics; Risk factors; Severity; Intensive unit care.

INTRODUCTION

In early December 2019, some cases of pneumonia with unknown cause, identified and named as SARS-Cov-2 later, occurred in Wuhan City, the capital city of Hubei Province (hereinafter former epicenter), China [1]. Results of gene sequence of the virus collected from infected patients showed a high similarity to virus in bats [2], and through haplotype analyses of 93 complete genomes of SARS-CoV-2, the source was identified as not from Huanan Seafood Market but from some other origin(s) [3]. As of April 26th, 2020, a total of 2,804,796 people were confirmed infected with SARS-CoV-2, including 193,710 deaths worldwide [4].

Till April 14th, 2020, over 80 retrospective case series had reported epidemiological and clinical characteristics of COVID-19 patients in or outside of former epicenter at

different stages of transmission and scale of location in China. Typical signs and symptoms of COVID-19 patients includes fever, dry cough, myalgia and fatigue, which were found similar to severe acute respiratory syndrome (SARS) with high mortality [5]. Clustering onset of the disease and higher susceptibility among older males with comorbidities were reported [6], and evidence from Li et al indicated that human-tohuman transmission had occurred since mid-December 2019 [7]. Some studies reported characteristics of the patients outside former epicenter, indicating relatively mild symptoms among them than in Hubei Province [8,9]. In addition, the confirmed patients sometimes assumed no typical symptoms and radiologic abnormalities [10], and more attention should be paid to hospital-related transmission [12]. In this study, we summarized, analyzed and compared confirmed cases from 53 retrospective studies of early stage in China, involving epidemiological characteristics, clinical outcomes, comorbidities, signs and symptoms on admission, complications, radiologic and laboratory findings on admission and treatment. Based on the 53 retrospective studies, more research was done concerning patients in/outside former epicenter, with/without severe condition and with/without ICU admission in terms of epidemiological and clinical characteristics, and risk factors of patients. Our study could be helpful for researchers and medical workers to have a more comprehensive and dynamic view of the characteristics of the disease of early stage in China.

MATERIALS AND METHODS

Search strategy and selection criteria

- 23 We searched PubMed, CNKI and Google Scholar for published retrospective studies
- 24 that described epidemiological and clinical characteristics of confirmed COVID-19
- patients in China by April 14th, 2020. Search terms included "coronavirus", "COVID"

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- and "2019-nCov" from December 2019 with no language restrictions. We also 1
- extensively searched the Internet for other published studies. Case report, research 2
- lacking key epidemiological information (e.g., gender or age) or radiological and 3
- laboratory findings, report on specific cases (e.g., newborn, familial cluster infections 4
- or selected for certain examination), research or data of patients outside China and of 5
- suspected were excluded. Finally, 53 studies were included. 6

Data analysis

7

8

- 9 Epidemiological and clinical characteristics were summarized, analyzed and compared
- in/outside former epicenter, with/without severe condition and with/without ICU 10
- admission. Categorical variables summarized as percentages were expressed as median 11
- and interquartile ranges (IOR), and differences were compared with the Mann-Whitney 12
- U test between patients in/outside former epicenter and with/without severe condition. 13
- We also explored univariable risk factors of the patients with severe condition or ICU 14
- admission in included studies, and Chi-squared test or Fisher's exact probability test 15
- and one-samples T test were used as appropriate. Statistical analyses were performed 16
- by SPSS Version 25.0 Software, and P value <0.05 was considered statistically 17
- significant with all tests 2-sided. 18

RESULTS

19

20

21

Overview of studies, epidemiological and clinical characteristics

- 22 This study systematically analyzed 53 published retrospective researches since the
- onset of SARS-CoV-2 as of April 14th, 2020 [5,6,8-58]. Among them, 20 studies were 23
- 24 in Chinese [20,23,29-31,44-58], and 33 were in English [5-19,21,22,24-28,32-43].
- Details of hospital(s), city/cities, province(s), admission period and number of patients 25

Epidemiological, Clinical Characteristics and Risk Factors for Severe Condition and ICU

	Admission of COVID-19 Patients of Early Stage in China: A review
1	in each study are in table S2.

1 Epidemiological and clinical characteristics of the 53 studies are in figure 1,2 and table 2 S1 and table S3-S36. Proportions of male were higher than 50% in 34 studies, ranging 3 from 30% to 77% [median=53.45%(48.48%-58.03%,IQR)] in 50 studies compared 4 with other three nationwide studies (51.4%,57.3% 5 and 58.2%). [median=51.6%(34.65%-62%)] of confirmed patients were aging>45-60 years old, and 6 7 smoking history was reported in 13 studies [median=7% (6.55%-24%, IQR)], but no evidence shows higher susceptibility for current smokers (table S1). Case fatality rates 8 9 (CFRs) were [median=0.75%(0%-9.53%,IQR)] in total, and [median=18%(9.6%-32.2%, IOR)] of the confirmed patients were in severe condition. 10 Results shows that [median=48%(31.08%-58.08%,IQR)] of the patients had at least one 11 comorbidity, and the top 5 comorbidities were hypertension [median=13.7%(6.7%-12 27.5%, IQR), diabetes [median=9.6%(5.86%-12%, IQR)], cardiovascular disease 13 14 [median=5.2%(2.68%-12.25%,IQR)],digestive disease [median=5.1%(3.91%-5.77%,IOR)] and cerebrovascular disease [median=2.8%(2.03%-4.73%,IOR)] (table 15 S1). As for signs and symptoms, 16 the most common fever one [median=83.15%(76.13%-92.15%,IQR)], 17 followed by cough [median=62.6%(50%-75.38%,IQR)], fatigue [median=31.7%(15.68%-53.93%,IQR)], 18 sputum production [median=18.1%(13%-34.69%,IQR)], chest tightness, myalgia, 19 20 inappetence, dyspnea, chills and others (table S1). Most complications occurred in about less than 10% of the patients (acute cardiac injury, other acute respiratory injury, 21 acute kidney injury and shock) in addition to ARDS [median=3.2%(0%-18.3%,IQR)] 22 23 and secondary infection [13.75%(10%-17.5%,IQR)]. Bilateral involvement [median=81.85%(68.81%-92.85%,IQR)], ground glass opacity 24 interlobular [median=75%(29.37%-92.15%,IQR)], thickening 25 septal

- 1 [median=60.85%(45.25%-77.33%,IQR)], pleural thickening [median=53.8%(12.3%-
- 2 66.8%,IQR)] and consolidation [median=41.8%(19.45%-49.73%,IQR)] were most
- 3 commonly radiological findings tested for the patients on admission. As for laboratory
- 4 findings, they were C-reactive protein > 3-6 mg/L [median=62.86%(52%-83.9%,IQR)],
- 5 C-reactive protein > 8-10 mg/L [median=60.7%(52%-75.2%,IQR)], lymphocyte count
- $6 < 0.8-1.5\times10^9/L$ [median=50.2%(33.6%-62.45%,IQR)], lactate dehydrogenase > 240-
- 7 250 U/L [median=38.15%(25.56%-63.25%,IQR)], hemoglobin < 110-130 g/L, white
- blood cell count $< 4 \times 10^9$ /L, D-dimer > 0.5 mg/L and procalcitonin > 0.5 ng/mL. Details
- 9 of other radiological, laboratory findings and treatments are in table S1.

Epidemiological and clinical characteristics of the patients in vs. outside the

former epicenter

10

11

- 13 In our study, 15 studies reported characteristics of COVID-19 patients in former
- 14 epicenter [5,6,10,12-16,22,24,28,44,45,47,53], 30 in one city or province outside
- former epicenter [7-9,17-19,26,27,29-31,33,34,36-43,46,49-5254-58] and five in more
- 16 than one city, province [20,21,25,35,48] or nationwide (in 30/31 provinces) [11,23,32].
- 17 Compared with the patients of studies outside former epicenter, patients in former
- 18 epicenter were older (age>45-60, y) [median=61.5%(52.95%-68.5%,IQR)] vs
- 19 [median=34.65%(29.03%-48.53%,IQR)] and had higher proportions of severe cases
- 20 [median=48.3%(36%-56.2%)] vs. [median=15.7%(7.95%-26.55%,IQR)] , CFRs
- 21 [median=10.7%(3.68%-15.43%,IOR)] vs. [median=0%(0%-0.73%,IOR)] and
- 22 comorbidities [median=46.75%(37.1%-53.2%,IQR)] vs. [median=28.6%(18.1%-
- 23 47.5%, IQR) significantly (P<0.05), including hypertension, cardiovascular disease
- 24 and diabetes (table S1). Higher proportions of the patients in former epicenter had
- 25 apparent signs and symptoms, including fever, highest temperature > 39°C, dyspnea

(p<0.01), chest tightness, fatigue and inappetence, but fewer patients had headache and 1 in asymptomatic infection in center (table S1). Higher proportions of complications, 2 including ARDS (p<0.05), acute cardiac injury, other acute respiratory injury, acute 3 kidney injury and shock, were reported in the patients in former epicenter. On admission, 4 most radiological and laboratory abnormalities were found in more patients in former 5 epicenter, including significantly (p<0.05) higher proportions of bilateral involvement 6 (chest radiological examination), white blood cell count > 10 × 10⁹/L, lactate 7 dehydrogenase > 240-250 U/L, C-reactive protein > 3-6 mg/L and C-reactive protein > 8 9 8-10 mg/L (Table S1). Invasive/non-invasive mechanical ventilation and ICU care were applied to higher proportions of the patients in former epicenter significantly (p<0.05). 10 11 Characteristics and univariable risk factors among patients in severe condition/ 12 **ICU** admission 13 Epidemiological and clinical characteristics of the COVID-19 patients were furtherly 14 15 divided into ICU/ non-ICU groups in two studies [5, 12], and into severe/ non-severe groups in 20 studies [10,11,15,17,21,24-26,29,33,35,37-39,43,44,49,51,53,55] (table 16 S37-S41). 17 Proportions of male, age>45-60 and comorbidities including hypertension, diabetes, 18 19 cardiovascular disease and COPD were significantly higher in patients with severe 20 condition (p<0.05, table S37), together with some signs, symptoms, radiological and laboratory findings on admission including dyspnea, lactate dehydrogenase > 225-250 21 U/L, bilateral involvement (radiological) and pleural effusion (radiological). 22 23 ICU cares were required in [median=13.75%(1.5%-24.15%,IQR)] of the patients, and risk factors (p<0.05) of them included hospitalized patients, with some comorbidities 24 including hypertension, cerebrovascular disease and diabetes, with some clinical 25

- characteristics including cough, dyspnea, sore throat, dizziness, respiratory rate >24
- breaths/ min, white blood cell count > 10×10^9 /L, hypersensitive troponin I > 28
- 3 pg/mL (99th percentile) and procalcitonin \geq 0.5 ng/mL (table S39).
- 4 Details of univariable risk factors of the patients with severe condition/ICU admission
- 5 are in table S39, and characteristics among patients with severe condition/ICU
- 6 admission are in table S37.

DISCUSSION

7

8

Results of our study showed that over half of the confirmed COVID-19 patients were 9 middle-aged and older male, with more cases of older people in former epicenter. 10 Proportions of the male patients in our study were higher than the male population in 11 China (t=2.36, p=0.022) as of 2019 (51.08%) and in Wuhan (t=1.03, p=0.32) as of 2017 12 (51%) [59, 60]. 14 studies reported 0%-48% of medical staff infection with relative 13 milder prognosis (p<0.05). As of Feb 11th, 2020, a total of 1716 (3.8%) medical staff 14 15 were infected with SARS-CoV-2, with death rate at 0.4%, six deaths in China [23]. One study was about two death cases of old male with a long smoking history but no 16 previous chronic underlying disease [6]. [median=7%(6.55%-24%,IQR)] of confirmed 17 patients had smoking history, lower than the proportion of current smokers (> 15 y, 18 19 27.7%) in China by 2015 markedly (t=-4.35, p<0.002) [26]. However, higher 20 percentages of former smokers were reported in patients with severe condition than non-severe [median=6.9%(5.2%-25%, IQR)] vs. [median=3.7%(1.3%-17%, IQR)], and 21 it was also connected with severe condition significantly (p>0.05). This may be because 22 23 of significantly higher ACE2 gene expression in lungs of former smokers, which is receptor for SARS-CoV-2 [62]. CFRs were [median=10.7%(3.68%-15.43%,IQR)] in 24 former epicenter and [median=0%(0%-0.73%,IQR)] outside according to included 25

studies, significantly higher condition 1 among patients with severe [median=6.5%(1.3%-17%,IQR)] vs. [median=0%(0%-0.9%,IQR)] **ICU** 2 admission (16.7%-38% vs 0%-4%). Epidemiological characteristics including male, 3 age > 45-60 and former smoker and hospitalized patients had significant connections 4 with severe condition or ICU admission (p<0.05). 5 Nearly all comorbidities were reported in higher proportions among the patients in 6 7 former epicenter, severe condition or with ICU admission than not, and some of them were also significant risk factors of severe condition or ICU admission among COVID-8 9 19 patients (P > 0.05) as a result of relatively poor immunity [6], including hypertension, cardiovascular disease, cerebrovascular disease, cardio-cerebrovascular disease, 10 11 diabetes, COPD, malignancy, immunosuppression. However, no evidence shows that proportions of the patients with hypertension (t=-3.12, p<0.01), cardiovascular disease 12 (t=-10.68, p<0.01), cerebrovascular disease (t=1.75, p=0.124), diabetes (t=0.72, p=0.124)13 14 p=0.477) and COPD (t=-3.07, p<0.01) in most studies were significantly higher than the national prevalency of China [63-67]. 15 However, we noticed that higher proportions of comorbidities, such as 16 immunodeficiency HIV and malignancy, were reported in some non-ICU and non-17 severe groups, indicating poor immunity. Result of minimally invasive pathological 18 19 examination by Xu et al also showed that severe immune injury in COVID-19 patients could be caused by overactivation of T cells, partially, manifested by increase of Th17 20 and high cytotoxicity of CD8 T cells [68]. Pulmonary and systemic inflammatory 21 22 responses associated with coronavirus are triggered by the innate immune system mostly when viruses are recognized, and this type of immune response can also inhibit 23 24 virus replication, promote virus clearance, induce tissue repair, and trigger a prolonged adaptive immune response against the viruses [69]. As a result, further research is 25

needed on how to neutralize harmful immune response and even make it a therapy for 1 2 COVID-19 patients especially with severe condition or ICU admission. With increasing human-to-human transmission of the virus, more confirmed COVID-3 19 patients were reported with no typical signs, symptoms, and radiologic, laboratory 4 findings on admission and with milder severity especially for studies outside Hubei. 5 This is most likely because of more patients were diagnosed earlier than those in Hubei 6 7 at the early stages of the SARS-CoV-2 outbreak. However, we cannot rule out that some of the characteristics and severity of the disease may change with human-to-human 8 9 transmission. Research of Bai et al and Hu et al indicated that patients under asymptomatic infection may have infectivity of the virus and even become a "super 10 infector" [70; 71]. In addition, there were reports of several cases of positive results or 11 false-negative results of RT-PCR test in diagnosis after discharge from hospital upon 12 treatment for even 5 to 13 days in China and Canada [72; 73; 74]. 13 Laboratory findings showed that alanine aminotransferase, aspartate aminotransferase, 14 15 total bilirubin, creatinine, creatine kinase, lactate dehydrogenase and hypersensitive troponin I of some the COVID-19 patients were beyond normal range, especially of 16 significant relevance for patients with severe conditions or ICU admission, indicating 17 liver, heart and kidney injury caused by SARS-CoV-2 [75-77]. 18 Lymphocytes count of more than half of the patients on admission were below the 19 20 normal range in our study [median=50.2%(33.6%-62.45%,IQR)], especially in severe [median=82.1%(71.8%-88.9%,IOR)], which probably had 21 connections with disease severity and mortality [78]. Under the requirement of avoiding 22 23 unnecessary outings and home isolation, some self-implementable traditional Chinese 24 medicine therapies helpful for improving immunity are recommended, including moxibustion, acupressure and some traditional exercises such as the Tai Chi Chuan 25

exercise [79-82]. In addition, they can relieve the burden of some comorbidities such

2 as cancer pain, diabetic peripheral neuropathy and asthma [80,83,84] by decreasing

duration, frequency or severity. As a result, they can also reduce medication intake,

especially those that may have considerable addiction and adverse events (e.g. opioid,

lidocaine medicated plaster and oral corticosteroids) [85,86].

6 Our study had several limitations. Firstly, there might be some repetition among data of

patients from the 53 researches included in our study because of the overlap in range of

time and location, and a table of some detailed information of the included studies are

in table S2. Secondly is the relatively small number of researches included in our study

for risk factor analysis among patients with/without ICU admission, so more researches

are needed on epidemiological and clinical characteristics of COVID-19 patients with

different ICU admission groups. Finally, results of our study are based on published

researches, while many issues of SARS-Cov-2 are still uncertain, so there may exist

bias in our study which justifies a modest interpretation of our results.

CONCLUSION

3

4

5

7

8

9

10

11

12

13

14

15

16

20

21

22

23

24

25

This study summarized, analyzed and compared epidemiological, clinical characteristics and estimated univariable risk factors among confirmed COVID-19 patients in/outside former epicenter, with/without severe condition, with/without ICU

admission of early stage in China. Higher proportions of patients were found to have

older age and more comorbidities, typical characteristics on admission and

complications either in former epicenter, with severe condition or ICU admission. No

evidence showed that patients who were male or had smoking history had higher

susceptibility, but they were significant risk factors for severe condition. Some self-

implementable TCM therapies should be recommended for immunity improvement,

- control of comorbidities and reduction of some medication intake. Limited evidence 1
- revealed that some characteristics of the disease might be changing with human-to-2
- human transmission, and more research, especially international collaboration, is 3
- needed. 4

5

6

8

9

16

17

19

20

23

ACKNOWLEDGEMENTS

7 We thank all the patients and authors involved in the researches included in our study.

CONTRIBUTORS

- OF and OZ put forwarded the study design. YaL, HY, LZ, and XL contributed to the 10
- study searching and data collection. OF, CH, OZ, HH, PZ, XL and XZ contributed to 11
- data summarization, analyzation and comparison. QF, WW and YaL contributed to 12
- statistical analysis. WW, QF, and YiL contributed to the design and drawing of tables 13
- 14 and figures. QF, QZ, HH, WW, YiL and CH contributed to the writing of the manuscript.
- All reviewed and approved the final version of the manuscript. 15

DECLARATION OF INTERESTS

We declare no competing interests. 18

REFERENCES

- 21 1 Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the
- 22 mystery and the miracle. J Med Virol 2020; published online Jan 16. doi:10.1002/jmv.25678.
- 24 2 Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of
- 25 the newly identified coronavirus may boost cross-species transmission from snake to human. J Med

- 1 Virol 2020; published online Jan 22. doi:10.1002/jmv.25682.
- 3 3 Yu WB, Tang GD, Zhang, L, Corlett RT. Decoding evolution and transmissions of novel
- pneumonia coronavirus using the whole genomic data. ChinaXiv 2020; published online Feb 21. 4
- 5 doi: 10.12074/202002.00033.
- 7 4 World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report-97. Apr 26,
- 8 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-
- 9 Covid-19.pdf?sfvrsn=d1c3e800 6.
- 11 5 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
- 12 in Wuhan, China. Lancet 2020; 395(10223):497-506.
- 14 6 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019
- 15 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507-
- 16 513.

2

6

10

13

17

20

24

- 7 Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-18
- 19 Infected Pneumonia. N Engl J Med 2020; published online Jan 29. doi:10.1056/NEJMoa2001316.
- 21 8 Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019
- 22 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;
- 23 published online Feb 19. doi:10.1136/bmj.m606.
- 25 9 Chang D, Lin M, Wei L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus
- 26 Infections Involving 13 Patients Outside Wuhan, China. JAMA 2020; published online Feb 7.
- 27 doi:10.1001/jama.2020.1623.
- 29 10 Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients with

- 1 Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; published online Apr 10.
- 2 doi:10.1001/jamaneurol.2020.1127.

3

6

10

14

18

21

25

- 4 11 Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N
- 5 Engl J Med 2020; published online Feb 28. doi:10.1056/NEJMoa2002032.
- 7 12 Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
- 8 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; published online Feb 7.
- 9 doi:10.1001/jama.2020.1585.
- 11 13. Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel
- 12 coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; published online Feb 06.
- doi:10.3760/cma.j.issn.1001-0939.2020.0005. (Chinese). 13
- 15 14 Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of
- 16 SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Med Infect
- Dis 2020; published online 2020 Feb 27. doi:10.1016/j.tmaid.2020.101606. 17
- 19 15 Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-
- 20 CoV-2 in Wuhan, China. Allergy 2020; published online Feb 19. doi:10.1111/all.14238.
- 22 16 Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary
- 23 hospitals in Hubei Province. Chin Med J (Engl) 2020; published online Feb 7.
- 24 doi:10.1097/CM9.0000000000000744.
- 26 17 Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;
- 27 published online Feb 27. doi:10.1016/j.jinf.2020.02.018.
- 29 18 Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu

- 1 Province: A Multicenter Descriptive Study. Clin Infect Dis 2020; published online Feb 29.
- 2 doi:10.1093/cid/ciaa199.

3

7

10

14

18

22

- 4 19 Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019
- novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J 5
- 6 Infect 2020; published online Feb 26. doi:10.1016/j.jinf.2020.02.016.
- 8 20 Liu C, Jiang ZC, Shao CX, et al. Zhonghua Gan Zang Bing Za Zhi 2020; 28(2):148-152.
- 9 doi:10.3760/cma.j.issn.1007-3418.2020.02.003 (Chinese).
- 11 21 Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of novel
- 12 coronavirus pneumonia caused by SARS-CoV-2. J Infect 2020; published online Feb 25.
- doi:10.1016/j.jinf.2020.02.017. 13
- 15 22 Cao J, Tu WJ, Cheng W, et al. Clinical Features and Short-term Outcomes of 102 Patients with
- 16 Corona Virus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; published online Apr 2. doi:
- 17 2020;ciaa243. doi:10.1093/cid/ciaa243.
- 19 23 The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The
- 20 Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)
- 21 — China, 2020. China CDC Weekly 2020; **2**(8): 113-122.
- 24 Li YK, Peng S, Li LQ, et al. Clinical and Transmission Characteristics of Covid-19 A 23
- 24 Retrospective Study of 25 Cases from a Single Thoracic Surgery Department. Curr Med Sci 2020;
- 25 published online Mar 30. doi: 10.1007/s11596-020-2176-2. doi:10.1007/s11596-020-2176-2
- 27 25 Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated with Severe and Critical
- 28 COVID-19 Pneumonia. Invest Radiol 2020; published online Feb 29. doi:
- 10.1097/RLI.0000000000000672. 29

1 2 26 Zhao W, Zhong Z, Xie X, et al. Relation Between Chest CT Findings and Clinical Conditions of 3 Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol 2020; 4 published online Mar 3. doi:10.2214/AJR.20.22976. 5 6 27 Xu T, Chen C, Zhu Z, et al. Clinical features and dynamics of viral load in imported and non-7 imported patients with COVID-19. Int J Infect Dis 2020; published online Mar 13. 8 doi:10.1016/j.ijid.2020.03.022. 9 28 Wang K, Kang S, Tian R, et al. Imaging manifestations and diagnostic value of chest CT of 10 11 coronavirus disease 2019 (COVID-19) in the Xiaogan area. Clin Radiol 2020; 75(5):341-347. 12 13 29 Tang GX, Li CH, et al. Clinical and CT findings of coronavirus disease 2019. Chinese Journal 14 of Respiratory and Critical Care Medicine 2020; 19(02):161-165. (Chinese). 15 16 30 Huang XQ, Nie LH, Li FM, et al. Analysis of Chinese Medical Characteristics of 35 Patients 17 with Novel Coronavirus Pneumonia. Journal of Emergency in Traditional Chinese Medicine 2020; 18 29(03):381-383+398. (Chinese). 19 20 31 Liu SD, Jiang XG, Ning HY, et al. Analysis of clinical features of 42 cases of new coronavirus 21 pneumonia. Shanghai Journal of Preventive Medicine 2020; published online Apr 19. doi: 22 10.19428/j.cnki.sjpm.2020.20092. (Chinese). 23 24 32 Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients 25 with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide 26 Analysis of China. Eur Respir J. 2020; published online Apr 8. doi:10.1183/13993003.00562-2020. 27 33 Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of 28 29 corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 2020;

1 **24**(6):3404-3410.

2

6

10

14

18

22

26

- 3 34 Dai H, Zhang X, Xia J, et al. High-resolution Chest CT Features and Clinical Characteristics of
- 4 Patients Infected with COVID-19 in Jiangsu, China. Int J Infect Dis 2020; published online Apr 6.
- 5 doi:10.1016/j.ijid.2020.04.003.
- 7 35 Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical
- 8 Features. Am J Respir Crit Care Med 2020; published online Apr 10. doi:10.1164/rccm.202002-
- 9 0445OC.
- 36 Peng L, Liu KY, Xue F, et al. Improved Early Recognition of Coronavirus Disease-2019 11
- 12 (COVID-19): Single-Center Data from a Shanghai Screening Hospital. Arch Iran Med 2020;
- 23(4):272-276. doi:10.34172/aim.2020.10. 13
- 37 Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical 15
- 16 specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci 2020;
- 17 16(10):1698–1707. doi:10.7150/ijbs.45357.
- 19 38 Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast
- 20 Chongqing. J Med Virol 2020; published online Mar 21. doi:10.1002/jmv.25783.
- 21 doi:10.1002/jmv.25783.
- 39 Qian GQ, Yang NB, Ding F, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized 23
- 24 Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM 2020;
- 25 published online Mar 17. doi:10.1093/qjmed/hcaa089
- 27 40 Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J
- Infect 2020; 80(5):e1-e6. 28

- 1 41 Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus
- 2 SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020; 47(5):1275–1280.

3

6

9

12

15

19

22

- 4 42 Wu J, Wu X, Zeng W, et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and
- 5 Its Relationship With Clinical Features. Invest Radiol 2020; 55(5):257–261.
- 7 43 Liu KC, Xu P, Lv WF, et al. CT manifestations of coronavirus disease-2019: A retrospective
- 8 analysis of 73 cases by disease severity. Eur J Radiol 2020; 126:108941.
- 44 Bin YF, Ji P, Liang XD, et al. Clinical characteristics of 55 hospitalized patients with COVID-19 10
- 11 in Wuhan, China. Journal of Guangxi Medical University 2020; 37(02):338-342. (Chinese).
- 13 45 Chen ZY, Chen ZY, Zhang XH, et al. Clinical manifestations and CT characteristics of corona
- virus disease 2019 (COVID-19). Radiologic Practice 2020; 35(03):286-290. (Chinese). 14
- 16 46 Diao KY, Han PL, Pang T, et al. The features and longitudinal changes on high-resolution
- 17 computed tomography for patients with coronavirus disease 2019. Chinese Journal of Respiratory
- 18 and Critical Care Medicine 2020; 19(02):166-171. (Chinese).
- 20 47 Din Y, Huang ZF, Zhao SC, et al. Clinical and imaging characteristics of corona virus disease
- 21 2019 (COVID-19. Radiologic Practice 2020; **35**(03):281-285. (Chinese).
- 48 Gao T, Xu YL, He XP, et al. Epidemiological and clinical characteristics of 40 patients with 23
- 24 coronavirus disease 2019 outside Hube. Chinese Journal of Respiratory and Critical Care Medicine
- 25 2020; 02:148-153. (Chinese).
- 27 49 Li YL, Shan NB, Sun W, et al. Comparative Study for Clinical Features between COVID-19
- Patients with Conventional Type and Heavy/Critical Type. Practical Journal of Cardiac Cerebral 28
- 29 Pneumal and Vascular Disease 2020; 28(03):14-19. (Chinese).

1 2 50 Liang YL, Yue F, Song L. Epidemiological and Clinical Characteristics of 28 Confirmed Cases 3 of Novel Coronavirus Pneumonia. Clinical research 2020; (04):1-3. (Chinese). 4 51 Lv R, Feng YY, Zhang YN, et al. CT features and analysis of 17 cases of COVID-19. International 5 6 Journal of Medical Radiology 2020; 02:131-134. (Chinese). 7 8 52 Mao Y, Cui X, Jiang ZC, et al. COVID-19 in Ankang District, Shaanxi: analysis of 24 cases of 9 TCM syndromes and clinical characteristics. Shaanxi Journal of Traditional Chinese Medicine 2020; 10 **04**:427-428+517. (Chinese). 11 12 53 Wang R, Xie LL, Du P, et al. Clinical characteristics of 96 hospitalized patients with coronavirus 13 disease 2019. Chinese Journal of Respiratory and Critical Care Medicine 2020; 02:144-147. 14 (Chinese). 15 16 54 Wang SB, Peng W, Yu L, et al. Clinical analysis of 17 cases of coronavirus disease 2019. Zhejiang 17 Medical Journal 2020; 04:365-367. (Chinese). 18 19 55 Xiang TX, Liu JM, Xu F, et al. Analysis of clinical characteristics of 49 patients with coronavirus 20 disease 2019 in Jiangxi. Chinese Journal of Respiratory and Critical Care Medicine 2020; 02:154-21 160. (Chinese). 22 56 Xu H, Li SH, Zhao CC, et al. Clinical and imaging features of 32 cases of corona virus disease 23 24 2019. Journal of Bengbu Medical College 2020; 02:150-153+155. (Chinese). 25 26 57 Yu SM, Wang ZX, Qin EQ, et al. Clinical characteristics of 25 patients with COVID-19. Chinese 27 Journal of Integrated Traditional and Western Medicine 2020; 03:369-370. (Chinese). 28 29 58 Yu JX, Zhang XM, Huang JS. Epidemiological and clinical characteristics of 87 cases of

1 coronavirus disease 2019 in Hangzhou. Zhejiang Medical Journal 2020; 04:318-320+324. (Chinese). 2 3 59 National Bureau of Statistics of China. Gender ratio of Chinese population as of 2018. 2018. 4 http://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0301&sj=2019 (Chinese). 5 60 Hu Z, Jin Y, Liu J, et al. POPULATION, EMPLOYMENT AND WAGE. In: Wuhan Municipal 6 7 Bureau of Statistics, ed. Wuhan statistical yearbook, 2018. China statistics press. Beijing: Aug 2018: 8 38. PDF: 9 http://117.136.191.144/cache/tjj.wuhan.gov.cn/Attachment/201901/201901041649116279.pdf?ich 10 args2=121- $\underline{12104410022478} \ b fef 43f 0a 1290 cad 7d 2961 da 8 cafe fab \ 10001002 \ 9c896 c 2f decbf 0d 1903251893$ 11 12 9a83798 8e1152749827eec2f887427ab963d394 (Chinese). 13 14 61 Hu SS, Gao RL, Wang Z, et, al. OUTLINE. In: National Center for Cardiovascular Diseases, 15 China, ed. REPORT ON CARDIOVASCULAR DISEASES IN CHINA 2018. Encyclopedia of 16 China Publishing House. Beijing: 2019: 3. PDF: Jan 17 http://117.128.6.21/cache/nccd.org.cn/Sites/Uploaded/File/2019/8/14-%E4%B8%AD%E5%9B% BD%E5%BF%83%E8%A1%80%E7%AE%A1%E7%97%85%E6%8A%A5%E5%91%8A2018% 18 19 EF%BC%88%E4%B8%AD%E6%96%87%E7%89%88%EF%BC%89.pdf?ich args2=462-20 11095509026575 6043db1fec4c58b2fce944dd03e44b67 10001002 9c896c2fdfcaf0d6973b51893 21 9a83798 2e40ada2aadd6db8d534753403e6cc64 (Chinese). 22 62 Cai GS. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene 23 24 expression of ACE2, the receptor of 2019-nCov. MedRxiv 2020; published online Feb 27. doi: 25 https://doi.org/10.1101/2020.02.05.20020107. 26 27 63 Liu LS, Wu ZS, Wang JG, et al. Prevalence of hypertension in Chinese population. In: China hypertension prevention and control guidelines revision committee, ed. Guidelines for the 28 29 prevention and treatment of hypertension in China, revised edition, 2018. People's Health Press.

1 Beijing: Oct 2018: 12-13 (Chinese). 2 3 64 Hu SS, Gao RL, Wang Z, et, al. The prevalence of cardiovascular disease. In: National Center 4 for Cardiovascular Diseases, China, ed. REPORT ON CARDIOVASCULAR DISEASES IN 5 CHINA 2018. Encyclopedia of China Publishing House. Beijing: Jan 2019: 12. PDF: 6 http://117.128.6.21/cache/nccd.org.cn/Sites/Uploaded/File/2019/8/14-%E4%B8%AD%E5%9B% 7 BD%E5%BF%83%E8%A1%80%E7%AE%A1%E7%97%85%E6%8A%A5%E5%91%8A2018% 8 EF%BC%88%E4%B8%AD%E6%96%87%E7%89%88%EF%BC%89.pdf?ich args2=462-9 11095509026575 6043db1fec4c58b2fce944dd03e44b67 10001002 9c896c2fdfcaf0d6973b51893 10 9a83798 2e40ada2aadd6db8d534753403e6cc64 (Chinese). 11 12 65 Wang LD, Liu JM, Yang Y, Peng B, Wang YL. The Prevention and Treatment of Stroke Still Face 13 Huge Challenges-Brief Report on Stroke Prevention and Treatment in China. Chinese 14 Circulation Journal 2018; **34**(02):105-119 (Chinese). 15 66 IDF DIABETES ATLAS, 9th edition 2019. Diabetes estimates in China (20-79 y). 2019. 16 17 https://diabetesatlas.org/data/en/country/42/cn.html. 18 19 67 Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease 20 in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 2018; 21 **391**(10131):1706–1717. 22 68 Ma CS, Deenick EK. Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol 2014; 23 24 **92**(1):64-71. 25 26 69 Xu Z, Shi L, Wang YJ, et al. Pathological findings of COVID-19 associated with acute respiratory 27 distress syndrome. The Lancet Respiratory Medicine 2020; published online Feb 18. doi:

28

29

https://doi.org/10.1016/S2213-2600(20)30076-X.

- 1 70 Li, G, Fan, Y, Lai, Y, et al. Coronavirus infections and immune responses. J Med Virol 2020; 92:
- 2 424-432.

3

6

10

13

17

21

24

- 4 71 Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA
- 5 2020; published online Feb 21. doi:10.1001/jama.2020.2565.
- 7 72 Hu ZL, Song C, Xu CJ, et al. Clinical Characteristics of 24 Asymptomatic Infections with
- 8 COVID-19 Screened among Close Contacts in Nanjing, China. medRxiv 2020; published online
- 9 Feb 25. doi: https://doi.org/10.1101/2020.02.20.20025619.
- 11 73 Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19.
- 12 JAMA 2020; published online Feb 27. doi:10.1001/jama.2020.2783.
- 14 74 Toronto Star. Ontario couple have recovered but are still testing positive for coronavirus. Feb 13,
- 15 2020. https://www.thestar.com/politics/provincial/2020/02/13/ontario-couple-have-recovered-
- 16 but-are-still-testing-positive-for-coronavirus.html.
- 75 Fan CB, Li K, Ding YH, Lu WL, Wang JQ. ACE2 Expression in Kidney and Testis May Cause 18
- 19 Kidney and Testis Damage After 2019-nCoV Infection. medRxiv 2020; published online Feb 13.
- doi: https://doi.org/10.1101/2020.02.12.20022418. 20
- 22 76 Fan ZY, Chen LP, Li J, et al. Clinical Features of COVID-19 Related Liver Damage. medRxiv
- 23 2020; published online Feb 28. doi: https://doi.org/10.1101/2020.02.26.20026971.
- 25 77 Zou X, Chen K, Zou JW, Han PY, Hao J, Han ZG. The single-cell RNA-seq data analysis on the
- 26 receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan
- 27 2019-nCoV infection. Front. Med. 2020; published online Mar 13. doi: 10.1007/s11684-020-0754-
- 0. 28

- 1 78 Diao B, Wang CH, Tan YJ, et al. Reduction and Functional Exhaustion of T Cells in Patients
- 2 with Coronavirus Disease 2019 (COVID-19). medRxiv 2020; published online Feb 20. doi:
- 3 https://doi.org/10.1101/2020.02.18.20024364.
- 79 Liao PC, Lin HH, Chiang BL, et al. Tai Chi Chuan Exercise Improves Lung Function and Asthma 5
- 6 Control through Immune Regulation in Childhood Asthma. Evid Based Complement Alternat Med
- 2019; published online Oct 23. doi:10.1155/2019/9146827. 7
- 9 80 Zheng G, Xiong Z, Zheng X, et al. Subjective perceived impact of Tai Chi training on physical
- 10 and mental health among community older adults at risk for ischemic stroke: a qualitative study.
- 11 BMC Complement Altern Med 2017; 17(1):221.
- 13 81 Yu SG, Jing XH, Tang Y, et al. Acupuncture and Moxibustion and Immunity: The Actuality and
- 14 Future. Zhen Ci Yan Jiu 2018; 43(12):747–753. (Chinese).
- 16 82 He Y, Guo X, May BH, et al. Clinical Evidence for Association of Acupuncture and Acupressure
- 17 With Improved Cancer Pain: A Systematic Review and Meta-Analysis. JAMA Oncol 2019;
- 18 **6**(2):271–278.

4

8

12

15

19

23

- 83 Fu Q, Yang H, Zhang L, et al. Traditional Chinese medicine foot bath combined with acupoint 20
- 21 massage for the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis
- 22 of 31 RCTs. Diabetes Metab Res Rev 2020; 36(2):e3218.
- 24 84 Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in
- 25 chronic pain: a systematic review and data synthesis. Pain 2015; 156(4):569-576.
- 27 85 Buksnys T, Armstrong N, Worthy G, et al. Systematic review and network meta-analysis of the
- efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin. Curr Med Res Opin 2020; 28
- 29 **36**(1):101–115.

- 2 86 Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among
- asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res 2018; 3
- 4 **19**(1):75.

1

5

FIGURES AND LEGENDS 6




Figure 1: Epidemiological characteristics, clinical outcomes, common comorbidities,

signs and symptoms on admission and complications.

1

2

Legend: This figure demonstrates distribution of proportions among epidemiological 1 2 characteristics, clinical outcomes, common comorbidities, signs and symptoms on admission and complications of confirmed COVID-19 patients in included studies. 3 Each brown or blue point represents one study conducted in or outside of former 4 epicenter respectively, with lines in same color shows median and interquartile range 5 of each subject (e.g. "Male", "Age>45-60") and group (i.e. in or outside of former 6 epicenter). Three studies, Liang 2020 A, Guan 2020 and Zhang 2020 A reported 7 epidemiological and clinical characteristics of the patients nation-widely, and they are 8 9 listed by lines in each subject for reference accordingly. (A) Smoker*: Includes current or(and) former smokers; Exposure A*: Exposure to the Huanan Seafood Market for 10 studies conducted in former epicenter, and exposure to former epicenter for studies 11 outside of former epicenter; Exposure B: Exposure to confirmed patients. (B) Cardio*: 12 Cardiovascular disease; Cerebro*: Cerebrovascular disease; COPD: Chronic 13 obstructive pulmonary disease; Digest*: Digestive disease; CLD*: Chronic liver 14 15 disease; Immuno*: immunodeficiency or HIV; CKD*: Chronic kidney disease. (C): >39°C*: The highest temperature >39°C during admission; Sputum*: Sputum 16 production; Tightness*: Chest tightness; Throat*: Sore throat; Asymptomatic*: 17 Asymptomatic infection cases. (D): ARDS: Acute Respiratory Distress Syndrome; 18 ACI*: Acute cardiac injury; oARI*: Other acute respiratory injury; AKI*: Acute kidney 19 20 injury.




Figure 2: Major radiologic, laboratory findings on admission and treatments.

1

	Admission of COVID-19 Patients of Early Stage in China: A review
1	Legend: This figure demonstrates distribution of proportions among major radiologic,
2	laboratory findings on admission and treatments of confirmed COVID-19 patients in
3	included studies. Each brown or blue point represents one study conducted in or outside
4	of former epicenter respectively, with lines in same color shows median and
5	interquartile range of each subject (e.g. "Bilateral*", "Local*") and group (i.e. in or
6	outside of former epicenter). Three studies, Liang 2020 A, Guan 2020 and Zhang 2020
7	A reported epidemiological and clinical characteristics of the patients nation-widely,
8	and they are listed by lines in each subject for reference accordingly. (A): Bilateral*:
9	Bilateral involvement; Local*: Local patchy opacity; GGO: Ground glass opacity;
10	Effusion*: Pleural effusion; Thickening*: Pleural thickening; Interlobular*:
11	Interlobular septal thickening; Paving*: Crazy-paving pattern; Air*: Air bronchogram
12	sign; Lymph node*: Lymph node enlargement. (B): WBC ↑*: White blood cell count >
13	9.5-10 × 10 9 /L; WBC \downarrow *: White blood cell count < 3.5-4 × 10 9 /L; NE \uparrow *: Neutrophil
14	count >5.8-7 × 10 ⁹ /L; NE \downarrow *: Neutrophil count < 1.8-2 × 10 ⁹ /L; Lymphocyte \downarrow *:
15	Lymphocyte count <0.8-1.5 \times 10 ⁹ /L; Hb \downarrow *: Hemoglobin < 110-130g/L; PLT \downarrow *:
16	Platelet count $<100-150 \times 10^{9}/L$; D-dimer $> 0.5*$: D-dimer $> 0.5 \text{mg/L}$; ALT $> 40-50*$:
17	Alanine aminotransferase > 40-50U/L; AST > 40-50*: Aspartate aminotransferase >
18	40-50U/L; LDH > 240-250*: Lactate dehydrogenase > 240-250U/L. (C): TBIL >21-
19	26*: Total bilirubin >21-26 mmol/L; PT >13.5-17: Prothrombin time >13.5-17s; PT <
20	10-10.5*: Prothrombin time <10-10.5s; CK >185-200*: Creatine kinase > 185-200U/L;
21	Cr > 73-87*: Serum creatinine > 73-87μmol/L; Cr > 111-133*: Serum creatinine > 111-
22	133μmol/L; PCT > 0.5*: Procalcitonin > 0.5ng/mL; BUN ↑*: Blood urea nitrogen >
23	7.6-9.5mmol/L; CRP > 3-6*: C-reactive protein > 3-6mg/L; CRP > 8-10*: C-reactive
24	protein > 8-10mg/L. (D): Oxygen*: Oxygen therapy; Invasive*: Invasive mechanical

- 1 ventilation; Non-invasive*: Non-invasive mechanical ventilation; CRRT: Continuous
- 2 renal replacement therapy; ECMO: Extracorporeal membrane oxygenation; Antibiotic*:
- Antibiotic treatment; Antiviral*: Antiviral treatment; CS: Corticosteroid therapy; IVIG: 3
- Intravenous immunoglobulin therapy; Antifungal*: Antifungal treatment; TCM: 4
- Traditional Chinese medicine; ICU: Intensive care unit care. 5

